<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00465751</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 211/04 SB</org_study_id>
    <nct_id>NCT00465751</nct_id>
  </id_info>
  <brief_title>Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism</brief_title>
  <official_title>Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether chenodeoxycholic acid decreases de novo&#xD;
      hepatic lipogenesis, hepatic fat content, hepatic triglyceride production and plasma&#xD;
      triglyceride concentrations and improves hepatic glucose metabolism in patients with the&#xD;
      metabolic syndrome, Familial Hypertriglyceridemia and Familial Combined Hyperlipidemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance has been found to be the key pathophysiological factor of the metabolic&#xD;
      syndrome and may precede the onset of impaired glucose tolerance, diabetes and dyslipidemia.&#xD;
      Recently, nonalcoholic fatty liver disease (NAFLD), has been identified as another feature of&#xD;
      this syndrome. Importantly, a close relation between liver fat content and hepatic insulin&#xD;
      sensitivity has been described. We hypothesize that activation of FXR with chenodeoxycholic&#xD;
      acid decreases hepatic de novo lipogenesis and subsequently hepatic fat content and&#xD;
      triglyceride production. The decrease in liver fat content will be associated with improved&#xD;
      hepatic insulin sensitivity and a decrease in hepatic glucose production.&#xD;
&#xD;
      Patients diagnosed with metabolic syndrome, familial hypertriglyceridemia or familial&#xD;
      combined hyperlipidemia will be recruited from the the outpatients department of the Division&#xD;
      of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Basel. Eligible&#xD;
      patients will be admitted to the CRC for metabolic studies, including baseline blood samples&#xD;
      for the measurement of hormones, cytokines and adipokines, euglycemic-hyperinsulinemic clamp&#xD;
      studies for the assessment of glucose turnover and insulin sensitivity and in vivo NMR&#xD;
      studies to determine intrahepatic and intramyocellular lipid content. Patients will&#xD;
      alternatively receive chenodeoxycholic acid and placebo. The study population will be&#xD;
      compared to a group of age, gender and weight matched normolipidemic controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma triglyceride concentrations</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatic insulin sensitivity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heptic triglyceride content</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Familial Hypertriglyceridemia</condition>
  <condition>Familial Combined Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chenodeoxycholic acid treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chenodeoxycholic acid</intervention_name>
    <description>chenodeoxycholic acid 500 mg capsules tid po</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo capsules</intervention_name>
    <description>placebo capsules containing mannitol tid po</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 and 65 years.&#xD;
&#xD;
          2. Patients with a metabolic syndrome defined by the presence of &gt;= 3 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Abdominal obesity (waist circumference &gt; 102 cm in men, &gt; 88 cm in women)&#xD;
&#xD;
               -  Fasting plasma triglycerides &gt; 1.7 mmol/l&#xD;
&#xD;
               -  HDL cholesterol &lt; 1.0 mmol/l in men and &lt; 1.3 mmol/l in women&#xD;
&#xD;
               -  Blood pressure &gt; 130/85 mmHg or antihypertensive medication&#xD;
&#xD;
               -  Fasting plasma glucose &gt; 6.1 mmol/l&#xD;
&#xD;
          3. Patients with Familial Combined Hyperlipidemia characterized by the following&#xD;
             criteria:&#xD;
&#xD;
               -  Fasting plasma triglycerides &gt; 1.7 mmol/l&#xD;
&#xD;
               -  Fasting plasma apolipoprotein B concentrations &gt; 1.2 g/l&#xD;
&#xD;
               -  Family history with hypertriglyceridemia and/or hypercholesterolemia present in&#xD;
                  at least 1 additional first degree family members&#xD;
&#xD;
          4. Patients with Familial Hypertriglyceridemia characterized by the following criteria:&#xD;
&#xD;
               -  Fasting plasma triglycerides &gt; 2.3 mmol/l&#xD;
&#xD;
               -  Family history of hypertriglyceridemia in at least 1 additional first degree&#xD;
                  family member&#xD;
&#xD;
               -  Absence of the metabolic syndrome as defined above&#xD;
&#xD;
          5. Controls fulfilling the following criteria:&#xD;
&#xD;
               -  Non smoking.&#xD;
&#xD;
               -  No current or previous organ or systemic disease (including diabetes and lipid&#xD;
                  disorders).&#xD;
&#xD;
               -  Plasma triglycerides and cholesterol within the normal range (see exclusion&#xD;
                  criteria).&#xD;
&#xD;
               -  Plasma glucose concentrations &lt;6.1 mmol/l Subjects meeting criterium 1 and any of&#xD;
                  the criteria 2. - 5. are eligible for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any significant hepatic, cardiac, pulmonary, renal, neurological, musculoskeletal,&#xD;
             hematological or endocrine disease.&#xD;
&#xD;
          2. Any form of primary or secondary hyperlipidemia other than the metabolic syndrome,&#xD;
             FHTG or FCHL. [These may include: Familial hypercholesterolemia and Familial defective&#xD;
             apolipoprotein B (to be assessed by family history and lipid profiles), and Familial&#xD;
             Dysbetalipoproteinemia (to be assessed by apo E genotyping), hypothyroidism, nephrotic&#xD;
             syndrome, diabetes mellitus, cholestatic liver disease, drug induced hyperlipidemia&#xD;
             (thiazides &gt; 25 mg/d, non cardioselective betablockers, isotretinoin, systemic&#xD;
             glucocorticoids, cyclosporin A, tacrolimus, non nucleoside HIV protease inhibitors)].&#xD;
&#xD;
          3. Plasma TG levels &gt; 12 mmol/l in the past or at any time point during the study.&#xD;
&#xD;
          4. History of acute pancreatitis&#xD;
&#xD;
          5. History of cardiovascular disease, i.e. coronary artery disease, cerebrovascular&#xD;
             disease, peripheral vascular disease, when assessed by medical history, physical exam.&#xD;
             Additionally, a stress test will be performed in subjects with MS and FCHL at risk for&#xD;
             CHD (see below).&#xD;
&#xD;
          6. Pregnant or Breast Feeding women&#xD;
&#xD;
          7. Woman of childbearing potential not using a reliable method of birth control such as&#xD;
             oral contraceptives or IUD.&#xD;
&#xD;
          8. Alcohol intake of greater than 1 drink daily.&#xD;
&#xD;
          9. Cigarette smokers&#xD;
&#xD;
         10. History of claustrophobia&#xD;
&#xD;
         11. Ferromagnetic implants including pacemakers.&#xD;
&#xD;
         12. Subjects refusing or unable to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Bilz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>April 24, 2007</study_first_submitted>
  <study_first_submitted_qc>April 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2007</study_first_posted>
  <last_update_submitted>March 8, 2012</last_update_submitted>
  <last_update_submitted_qc>March 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type IV</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

